China's medical products administrator granted Broncus Holding (HKG:2216) marketing approval for its disposable lung radiofrequency ablation catheter, according to a Monday filing with the Hong Kong bourse.
The device, branded BroncAblate, will help with ultra-minimally invasive interventional therapy for lung cancer, the filing said.
Lung radiofrequency ablation uses heat generated by radio waves to destroy cancer cells.
Shares in Broncus soared 35% during morning trading on Tuesday.